Tables of Rules
HIV- 2

Nucleoside and Nucleotide reverse transcriptase inhibitors Protease inhibitors

Non-Nucleoside reverse transcriptase inhibitors Fusion inhibitors

HIV - 2 Integrase strand transfer inhibitors


NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS
[1]

  Mutations associated with resistance Mutations associated with « possible resistance »
ZDV
Q151M
S215A/C/F/L/Y + 1 mutation among K65R, N69S/T, K70R, Y115F, K223R

  S215A/C/F/L/Y
3TC/FTC
M184I/V

K65R
ABC
K65R
Q151M
M184I/V + 1 mutation among: L74V, Y115F
2 mutations among: D67N, K70N/R, M184V/I, S215A/C/F/L/Y
TDF/TAF
K65R
Q151M + V111I
 
ZDV: zidovudine, 3TC: lamivudine, FTC: emtricitabine, ABC: abacavir, TDF: tenofovir, TAF : tenofovir alafenamide
Didanosine and stavudine are not recommended.


PROTEASE INHIBITORS [1]

  Mutations associated with resistance Mutations associated with « possible resistance »
LPV
2 mutations among: I82F, I84V, L90M
I54M
V47A

V62A + L99F
1 mutation among: I82F, I84V, L90M

DRV I50V
I54M
I84V + L90M
1 mutation among: I84V, L90M
LPV: lopinavir, DRV : darunavir
For indinavir and saquinavir refer to previous rules (Version 27, September 2017).
Atazanavir and tipranavir are not recommended.


INTEGRASE STRAND TRANSFER INHIBITORS [1]

  Mutations associated with resistance Mutations associated with "possible resistance"
RAL N155H/R
Q148K/R
E92Q + T97A
Y143C/G/R + 1 mutation among: E92Q, T97A

E92Q
Y143C/G/R
EVG E92G/Q
Q148K/R
N155H
T97A + Y143C
Y143C
DTG
Q148K
G140S + Q148R
E92Q + N155H
T97A + N155H

Q148R
N155H
E92Q
T97A + Y143C
RAL: raltegravir, EVG : elvitegravir, DTG: dolutegravir.

NON-nuclEosidE REVERSE TRANSCRIPTASE INHIBITORS

Naturally resistant to all NNRTI [2]

FUSION INHIBITOR

Naturally resistant to T20 [2]


References